James Matcham
- Hematology top 1%
- Acute Myeloid Leukemia Research 7
- Hematopoietic Stem Cell Transplantation 6
- Biochemistry top 5%
- Statistics and Probability top 5%
- Statistical Methods in Clinical Trials 10
- Genetics top 10%
- Oncology top 10%
- Neutropenia and Cancer Infections 4
-
- Health Systems, Economic Evaluations, Quality of Life 6
-
- Computational Drug Discovery Methods 3
-
- Pharmaceutical industry and healthcare 3
-
- Meta-analysis and systematic reviews 3
James Matcham
25 papers receiving 1.3k citations
Hit Papers
Peers
Comparison fields: 5 of 120
- Hematology 658
- Biochemistry 90
- Statistics and Probability 121
- Genetics 139
- Oncology 320
Countries citing papers authored by James Matcham
This map shows the geographic impact of James Matcham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James Matcham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James Matcham more than expected).
Fields of papers citing papers by James Matcham
This network shows the impact of papers produced by James Matcham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James Matcham. The network helps show where James Matcham may publish in the future.
Co-authorship network
The 25 scholars most cited alongside James Matcham, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2018 | 1 | |
| 2 | Impact of a five-dimensional framework on R&D productivity at AstraZenecabreakdown → | 2018 | 271 |
| 3 | 2017 | 44 | |
| 4 | 2015 | 2 | |
| 5 | 2013 | 18 | |
| 6 | 2011 | 31 | |
| 7 | 2010 | 6 | |
| 8 | 2010 | 13 | |
| 9 | 2010 | 13 | |
| 10 | 2009 | 21 | |
| 11 | 2007 | 13 | |
| 12 | 2006 | 15 | |
| 13 | 2003 | 67 | |
| 14 | 2003 | 267 | |
| 15 | 2002 | 2 | |
| 16 | 1999 | 83 | |
| 17 | 1997 | 32 | |
| 18 | 1997 | 11 | |
| 19 | Results of a randomised, double-blind placebo controlled phase III study of filgrastim in remission induction and early consolidation therapy for adults with de-novo acute myeloid leukemia | 1995 | 12 |
| 20 | 1991 | 6 |
About James Matcham
James Matcham is a scholar working on Statistics and Probability, Hematology, Statistics, Probability and Uncertainty, Genetics and Pharmacology, having authored 26 papers that have together received 1.3k indexed citations. Recurring topics across this work include Statistical Methods in Clinical Trials (10 papers), Acute Myeloid Leukemia Research (7 papers), Health Systems, Economic Evaluations, Quality of Life (6 papers), Hematopoietic Stem Cell Transplantation (6 papers), Neutropenia and Cancer Infections (4 papers), Computational Drug Discovery Methods (3 papers), Pharmaceutical industry and healthcare (3 papers) and Meta-analysis and systematic reviews (3 papers). The work is most often cited by research in Hematology (658 citations), Biochemistry (90 citations), Statistics and Probability (121 citations), Genetics (139 citations) and Oncology (320 citations). James Matcham has collaborated with scholars based in United Kingdom, Germany and France. Frequent co-authors include Gerhard Heil, Miguel Á. Sanz, Klaus Lechner, Jeff Szer, Alan Barge, Dieter Hoelzer, John A. Liu Yin, L. Noens, Arnold Ganser and Caroline O’Brien. Their work appears in journals such as Pharmaceutical Statistics, Blood, Statistics in Biopharmaceutical Research, Bone Marrow Transplantation and British Journal of Haematology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.